Treatment of Psoriasis and Psoriatic Arthritis

New Interleukin-23 Pathway Inhibitors in Dermatology

(2011) Marta Kurzeja et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Briakinumab for the Treatment of Plaque Psoriasis

(2011) Pawel Traczewski et al.   BIODRUGS

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

(2011) K. Reich et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Insights in the Immunologic Basis of Psoriasis

(2010) Kristine E. Nograles et al.   SEMINARS IN CUTANEOUS MEDICINE AND SURGERY

Psoriasis genetics: breaking the barrier

(2010) Elisha D.O. Roberson et al.   TRENDS IN GENETICS

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

(2009) Arthur Kavanaugh et al.   ARTHRITIS AND RHEUMATISM

Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis

(2009) Vinod Chandran et al.   JOURNAL OF AUTOIMMUNITY

Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8

(2009) Dipyaman Ganguly et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

(2008) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

(2008) J. Schmitt et al.   BRITISH JOURNAL OF DERMATOLOGY

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

(2008) A.K. Brimhall et al.   BRITISH JOURNAL OF DERMATOLOGY

From conventional to cutting edge: the new era of biologics in treatment of psoriasis

(2008) Julia Tzu et al.   Dermatologic Therapy

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

(2007) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY